DMK PHARMACEUTICALS CORP (DMK) Stock Earnings & Estimates
NASDAQ:DMK - US00547W3079 - Common Stock
0.232 USD
+0 (+0.91%)
0.1665 USD
-0.07 (-28.23%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 2.78M -87.43% | 2.21M -20.50% | 4.76M 115.38% | 1.484M -68.82% | 4.688M 215.90% | 17.299M 269.01% | |
| EBITDA YoY % growth | -28.07M -7.59% | -30.63M -9.12% | -23.58M 23.02% | N/A | N/A | N/A | |
| EBIT YoY % growth | -31.68M -9.13% | -32.07M -1.23% | -25.06M 21.86% | -30.841M -23.07% | -30.005M 2.71% | -21.391M 28.71% | |
| Operating Margin | -1,139.57% | -1,451.13% | -526.47% | -2,078.26% | -640.04% | -123.66% | |
| EPS YoY % growth | -0.62 -12.73% | -4.49 -624.19% | N/A | -4.43 | -0.97 78.13% | -0.43 55.21% |
All data in USD
| Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.42 | -0.52 | -0.21 | -0.20 19.20% | -0.20 52.38% |
| Revenue Q2Q % growth | -100.00% | 234.32K -83.84% | 702.96K 6,929.60% | 1.641M 18,012.58% | 2.11M |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -3.024M 30.32% | -3.639M 43.41% | -3.591M 68.23% | -3.495M -11.00% | -3.446M -13.96% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2022 Q2Q % growth | -4.20 -6,900.00% | -2.47 | -1.73 | -69.73% |
| Q1 2022 Q2Q % growth | -4.90 -3,983.33% | -2.12 | -2.78 | -131.02% |
| Q4 2021 Q2Q % growth | -4.20 -1,650.00% | -3.18 | -1.02 | -32.01% |
| Q3 2021 Q2Q % growth | -0.11 -10.00% | -0.04 | -0.07 | -172.28% |
| Q2 2021 Q2Q % growth | -0.06 53.85% | -0.06 | 0.00 | -8.01% |
| Q1 2021 Q2Q % growth | -0.12 20.00% | -0.06 | -0.06 | -98.02% |
| Q4 2020 Q2Q % growth | -0.24 -200.00% | -0.06 | -0.18 | -296.04% |
| Q3 2020 Q2Q % growth | -0.10 16.67% | -0.05 | -0.05 | -85.66% |
| Q2 2020 Q2Q % growth | -0.13 18.75% | -0.08 | -0.05 | -67.88% |
| Q1 2020 Q2Q % growth | -0.15 21.05% | -0.06 | -0.09 | -162.07% |
| Q4 2019 Q2Q % growth | -0.08 | -0.04 | -0.04 | -116.00% |
| Q3 2019 Q2Q % growth | -0.12 | -0.09 | -0.03 | -39.78% |
| Q2 2019 Q2Q % growth | -0.16 | -0.13 | -0.03 | -21.86% |
| Q1 2019 Q2Q % growth | -0.19 | -0.17 | -0.02 | -14.01% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2023 Q2Q % growth | 9.06K -99.40% | % | ||
| Q2 2023 Q2Q % growth | 10K 120.00% | % | ||
| Q1 2023 Q2Q % growth | 1.45M 26.09% | % | ||
| Q4 2022 Q2Q % growth | 2.15M 276.23% | % | ||
| Q3 2022 Q2Q % growth | 1.51M 98.68% | % | ||
| Q2 2022 Q2Q % growth | -50K -103.91% | 1.028M | -1.078M | -104.86% |
| Q1 2022 Q2Q % growth | 1.15M -17.27% | % | ||
| Q4 2021 Q2Q % growth | -1.22M -279.41% | 2.846M | -4.066M | -142.87% |
| Q3 2021 Q2Q % growth | 760K -12.64% | % | ||
| Q2 2021 Q2Q % growth | 1.28M 137.32% | 3.123M | -1.843M | -59.01% |
| Q1 2021 Q2Q % growth | 1.39M -70.17% | 3.5M | -2.11M | -60.29% |
| Q4 2020 Q2Q % growth | 680K -87.73% | 5.764M | -5.084M | -88.20% |
| Q3 2020 Q2Q % growth | 870K -85.25% | 7.048M | -6.178M | -87.66% |
| Q2 2020 Q2Q % growth | -3.43M -159.55% | 5.319M | -8.749M | -164.49% |
| Q1 2020 Q2Q % growth | 4.66M -5.09% | 6.46M | -1.8M | -27.86% |
| Q4 2019 Q2Q % growth | 5.54M | 7.07M | -1.53M | -21.64% |
| Q3 2019 Q2Q % growth | 5.9M | 6.439M | -539K | -8.37% |
| Q2 2019 Q2Q % growth | 5.76M | 5.899M | -139K | -2.36% |
| Q1 2019 Q2Q % growth | 4.91M | 5.849M | -939K | -16.05% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | N/A | N/A | N/A |
| Revenue | N/A | N/A | N/A | N/A |